Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-0360324
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
PD-0360324 is a fully human immunoglobulin G2 monoclonal antibody that targets macrophage colony-stimulating factor (M-CSF or CSF1). By binding to M-CSF with high affinity and selectivity, it inhibits the interaction of M-CSF with its receptor (CSF1R), leading to suppression of certain monocyte populations and modulation of tissue macrophage activity. The drug was developed by Pfizer as an anti-inflammatory and antineoplastic agent for conditions such as solid tumors, rheumatoid arthritis, cutaneous lupus erythematosus, and pulmonary sarcoidosis. Clinical studies have shown pharmacodynamic effects on monocytes but limited clinical efficacy in some autoimmune indications[1][2][3][5].
- Other names
- MCSF mAb (RA)Macrophage colony stimulating factor monoclonal antibody (rheumatoid arthritis)
02
Targets
CSF1 (Colony-stimulating factor 1)
Beyond the preview
Go deeper on PD-0360324.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-0360324.